Sanxing Medical: The abnormal fluctuations in stock trading do not involve any undisclosed major issues that need to be disclosed.

Samsung Medical announced that the company's stock price had a cumulative deviation of more than 20% from the closing price on March 5th, 6th, and 9th in 2026, which was considered abnormal trading volatility. As of March 9th, the company's trailing P/E ratio was 23.06, P/B ratio was 3.87, and turnover rate was 5.49%, deviating from industry data for the same period. After conducting a self-inspection, the company confirmed that its production and operations were normal, and there were no undisclosed significant events that should have been disclosed. The controlling shareholder and the actual controller did not engage in any trading of the company's stock during this period. Investors were reminded to be cautious of trading risks.